参考文献/References:
[1] De La Vieja A, Dohan O, Levy O, et al. Molecular analysis of the sodium/iodide symporter:impact on thyroid and extrathyroid pathophysiology[J]. Physiol Rev, 2000, 80(3):1083-1105.
[2] Spitzweg C, Joba W, Eisenmenger W, et al. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa[J]. J Clin Endocrinol Metab, 1998, 83(5):1746-1751.
[3] Huang M, Batra RK, Kogai T, et al. Ectopie expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer[J]. Cancer Gene Ther, 2001, 8(8):612-618.
[4] Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers[J]. Thyroid, 2002, 12(1):19-26.
[5] Wenzel A, Upadhyay G, Schmitt TL, et al. Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS[J]. Mol Cell Endocrinol, 2003, 213(1):99-108.
[6] Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res, 1999, 59(9):2136-2141.
[7] Spitzweg C, O’Connor MK, Bergert ER, et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter[J]. Cancer Res, 2000, 60(22):6526-6530.
[8] Kakinuma H, Bergert ER, Spitzweg C, et al. Probasin promoter (ARR (2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer[J]. Cancer Res, 2003, 63(22):7840-7844.
[9] Dwyer RM, Bergen ER, O’Connor MK, et al. In vivo radioiodide imaging and treatment of breast cancer xenografis after MUC1-driven expression of the sodium iodide symporter[J]. Clin Cancer Res, 2005, 11(4):1483-1489.
[10] Dwyer RM, Bergert ER, O’Connor MK, et al. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice[J]. Gene Ther, 2006, 13(1):60-66.
[11] Sieger S, Jiang S, Schonsiegel F, et al. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3)[J]. Eur J Nucl Med Mol Imaging, 2003, 30(5):748-756.
[12] Dingli D, Diaz RM, Bergert ER, et al. Genetically targeted radiotherapy for multiple myeloma[J]. Blood, 2003, 102(2):489-496.
[13] Schipper ML, Weber A, Behe M, et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells[J]. Cancer Res, 2003, 63(6):1333-1338.
[14] Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer[J]. Gene Ther, 2005, 12(3):272-280.
[15] Cengic N, Baker CH, Schǚtz M, et al. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression[J]. J Clin Endocrinol Metab, 2005, 90(8):4457-4464.
[16] Schmutzler C, Winzer R, Meissner-Weigl J, et al. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J]. Biochem Biophys Res Commun, 1997, 240(3):832-838.
[17] Kogai T, Schahz JJ, Johnson LS, et al. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line[J]. Proe Natl Acad Sci USA, 2000, 97(15):8519-8524.
[18] Kogai T, Kanamoto Y, Che LH, et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models[J]. Cancer Res, 2004, 64(1):415-422.
[19] Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells[J]. Endocrinology, 2003, 144(8):3423-3432.
[20] Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells[J]. J Clin Endocrinol Metab, 2006, 91(1):69-78.
[21] Dadachova E, Bouzahzah B, Zuckier LS, et al. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS)[J]. Nucl Med Biol, 2002, 29(1):13-18.
[22] Carlin S, Akabani G, Zalutsky MR. In vitro eytotoxieity of (211)atastatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter[J]. J Nucl Med,2003,44(11):1827-1838.
[23] Dwyer RM, Schatz SM, Bergert ER, et al. A preclinieal large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer[J]. Mol Ther, 2005, 12(5):835-841.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[11]郭睿,李彪.钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展[J].国际放射医学核医学杂志,2010,34(3):147.
GUO Rui,LI Biao.Advances of radioiodine therapy of tumor induced by sodium iodide symporter gene[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):147.
[12]郑薇,谭建.甲状腺癌的基因治疗[J].国际放射医学核医学杂志,2007,31(4):197.
ZHENG Wei,TAN Jian.Gene therapy of thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):197.